New insights into the biology of the acute phase response

Journal of Clinical Immunology

Volumn 19, Issue 4, 1999, Pages 203-214

  Suffredini, Anthony F ^a   Fantuzzi, Giamila ^b   Badolato, Raffaele ^c   Oppenheim, Joost J ^d   O'Grady, Naomi P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute phase proteins; Acute phase response; Human endotoxemia; Serum amyloid A

Indexed keywords

AMYLOID P COMPONENT; C REACTIVE PROTEIN; CD11B ANTIGEN; CD14 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MANNOSE BINDING PROTEIN; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PHASE RESPONSE; ANTIGEN RECOGNITION; CHEMICAL STRUCTURE; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; PATTERN RECOGNITION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; APOLIPOPROTEINS; ENDOTOXEMIA; HUMANS; MODELS, IMMUNOLOGICAL; SERUM AMYLOID A PROTEIN;

EID: 0032875608     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020563913045     Document Type: Review

References (87)

1. Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74-80, 1994
2. Medzhitov R, Janeway CA, Jr: Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol 9:4-9, 1997
3. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272:50-53, 1996
4. Ulevitch RS, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457, 1995
5. Pugin J, Heumann ID, Tomasz A, et al.: CD14 is a pattern recognition receptor. Immunity 1:509-516, 1994
6. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394-397, 1997
7. Yang RB, Mark MR, Gray A, et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395:284-288, 1998
8. Tilg H, Dinarello CA, Mier JW: IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 18:428-432, 1997
9. Alcorn JM, Fierer J, Chojkier M: The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 15:122-129, 1992
10. Heuertz RM, Xia D, Samols D, Webster RO: Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expression C-reactive protein. Am J Physiol 266:L649-L654, 1994
11. Benigni F, Fantuzzi G, Sacco S, et al.: Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 87: 1851-1854, 1996
12. Kopf M, Baumann H, Freer G, et al.: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342, 1994
13. Yoshida K, Taga T, Saito M, et al.: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407-411, 1996
14. Taga T: GP130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797-819, 1997
15. Zheng H, Fletcher D, Kozak W, et al.: Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 3:9-19, 1995
16. Fantuzzi G, Dinarello CA: The inflammatory response in interleukin-1β-deficient mice: Comparison with other cytokine-related knock-out mice. J Leukocyte Biol 59:489-493, 1996
17. Fattori E, Cappelletti M, Costa P, et al.: Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180:1243-1250, 1994
18. Kozak W, Zheng H, Conn CA, Soszynski D, van der Ploeg LH, Kluger MJ: Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1 beta-deficient mice. Am J Physiol 269:R969-R977, 1995
19. Fantuzzi G, Ku G, Harding MW, et al.: Response to local inflammation of IL-1 beta-converting enzyme-deficient mice. J Immunol 158:1818-1824, 1997
20. Leon LR, Conn CA, Glaccum M, Kluger MJ: IL-1 type I receptor mediates acute phase response to turpentine, but not lipopolysaccharide, in mice. Am J Physiol 271:R1668-R1675, 1996
21. Leon LR, Kozak W, Peschon J, Kluger MJ: Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice. Am J Physiol 272:R563-R569, 1997
22. Fantuzzi G, Zheng H, Faggioni R, et al.: Effect of endotoxin in IL-1 beta-deficient mice. J Immunol 157:291-296, 1996
23. Shornick LP, De Togni P, Mariathasan S, et al.: Mice deficient in IL-1 beta manifest impaired contact hypersensitivity to trinitrochlorobenzone. J Exp Med 183:1427-1436, 1996
24. Rothe J, Lesslauer W, Lotscher H, et al.: Mice lacking the tumour necrosis factor receptor I are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1993
25. Car BD, Eng VM, Schnyder B, et al.: Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 179:1437-1444, 1994
26. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue [see comments]. Nature 372:425-432, 1994 [Erratum appears in Nature 374(6521):479, 1995]
27. Grunfeld C, Zhao C, Fuller J, et al.: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97:2152-2157, 1996
28. Saraff P, Frederich RC, Turner EM, et al.: Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia. J Exp Med 185:171-175, 1997
29. Tartaglia LA, Dembski M, Weng X, et al.: Identification and expression cloning of a leptin receptor. OB-R. Cell 83:1263-1271, 1995
30. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C: IL-1 beta mediates leptin induction during inflammation. Am J Physiol 274:R204-R208, 1998
31. Faggioni R, Fuller J, Moser A, Feingold KR, Grunfeld C: LPS-induced anorexia in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice. Am J Physiol 273:R181-R186, 1997
32. Faggioni R, Fantuzzi G, Gabay C, et al.: Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol 276:R136-R142, 1999
33. Takahashi N, Waelput W, Guisez Y: Leptin is an endogenous protective protein against the toxicity exerted by tumor necrosis factor. J Exp Med 189:207-212, 1999
34. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94:2557-2562, 1997
35. Dong ZM, Gutierrez-Ramos JC, Coxon A, Mayadas TN, Wagner DD: A new class of obesity genes encodes leukocyte adhesion receptors. Proc Natl Acad Sci USA 94:7526-7530, 1997
36. Steel DM, Whitehead AS: The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15:81-88, 1994
37. Sipe J: The acute-phase response. In Immunophysiology: The Role of Cells and Cytokines in Immunity and Inflammation, JJ Oppenheim, EM Shevach (eds). New York, Oxford University Press, 1990, pp 259-273
38. Beach CM, De Beer MC, Sipe JD, Loose LD, De Beer FC: Human serum amyloid A protein. Complete amino acid sequence of a new variant. Biochem J 282:615-620, 1992
39. Watson G, Coade S, Woo P: Analysis of the genomic and derived protein structure of a novel human serum amyloid A gene, SAA4. Scand J Immunol 36:703-712, 1992
40. Bausserman LL, Herbert PN, McAdam KP: Heterogeneity of human serum amyloid A proteins. J Exp Med 152:641-656, 1980
41. Hoffman JS, Benditt EP: Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density lipoprotein in primary mouse hepatocyte culture. J Biol Chem 257:10518-10522, 1982
42. Husebekk A, Skogen B, Husby G: Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Displacement of SAA from the HDL-SAA complex by apo AI and apo AII. Scand J Immunol 25:375-381, 1987
43. Stone MJ: Amyloidosis: A final common pathway for protein deposition in tissues. Blood 75:531-545, 1990
44. Meck RL, Eriksen N, Benditt EP: Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc Natl Acad Sci USA 89:7949-7952, 1992
45. Liang JS, Sipe JD: Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 36:37-46, 1995
46. Badolato R, Wang JM, Murphy WJ, et al.: Serum amyloid A is a chemoattractant: Induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180:203-209, 1994
47. Xu L, Badolato R, Murphy WJ, et al.: A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 155:1184-1190, 1995
48. Musso T, Bresciani S, Ponzi AN, Wang J, Turano A, Badolato R: Serum amyloid A enhances PMN-mediated anti-Candida activity and stimulates the production of anion superoxide. J Leukocyte Biol 194:194, 1996 (abstract)
49. Bausserman LL, Herbert PN, Rodger R, Nicolosi RJ: Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim Biophys Acta 792;186-191, 1984
50. Lavie G, Zucker-Franklin D, Franklin EC: Elastase-type proteases on the surface of human blood monocytes: Possible role in amyloid formation. J Immunol 125:175-180, 1980
51. Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O: Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol 156:1189-1195, 1996
52. Badolato R, Johnston JA, Wang JM, et al.: Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 155:4004-4010, 1995
53. Su SB, Gong W, Gao JL, et al.: A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189:395-402, 1999
54. Rutledge BJ, Rayburn H, Rosenberg R, et al.: High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol 155:4838-4843, 1995
55. Linke RP, Bock V, Valet G, Rothe G: Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem Biophys Res Commun 176:1100-1105, 1991
56. Suffredini AF, O'Grady NP: Pathophysiologic responses to endotoxin in humans. In Endotoxin in Health and Disease, 1st ed, H Braude, DC Morrison, SM Opal, SN Vogel (eds). New York. Marcel Dekker, 1999
57. Pajkrt D, Van der Poll T, Levi M, et al.: Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 89:2701-2705, 1997
58. Kuhns DB, Alvord WG, Gallin JI: Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 171:145-152, 1995
59. Van der Poll T, Calvano SE, Kumar A, et al.: Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 86:2754-2759, 1995
60. Suffredini AF, Harpel PC, Parrillo JE: The promotion and subsequent inhibition of plasminogen following the intravenous endotoxin administration to normal humans. N Engl J Med 320:1165, 1989
61. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038-5045, 1995
62. Van Deventer SJH, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520-2526, 1990
63. DeLa Cadena RA, Suffredini AF, Page JD, Kaufman N, Parrillo JE, Colman RW: Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 81:3313-3317, 1993
64. Michie HR, Manogue KR, Spriggs DR, et al.: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486, 1988
65. Preas HL, Reda D, Tropea M, et al.: Effects of recombinant soluble type I IL-1 receptor on human inflammatory responses to endotoxin. Blood 88:2465-2472, 1996
66. Granowitz E, V., Santos AA, Poutsiaka DD, et al.: Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 338:1423-1424, 1991
67. Fong Y, Moldawer LL, Marano M, et al.: Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 142:2321-2324, 1989
68. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J Exp Med 173:1021-1024, 1991
69. Elin RJ, Wolff SM, McAdam KPWJ, et al.: Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 144:329-336, 1981
70. Revhaug A, Michie HR, Manson JM, et al.: Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg 123:162-170, 1988
71. Suffredini AF, Fromm RE, Parker MM, et al.: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280-287, 1989
72. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parrillo JE: Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis 145:1398-1403, 1992
73. Boujoukos AJ, Martich GD, Supinski E, Suffredini AF: Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J Appl Physiol 74:3027-3033, 1993
74. Fong Y, Marano MA, Moldawer LL, et al.: The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896-1904, 1990
75. Preas HL, Tropea M, Reda D, et al.: Bronchial instillation of endotoxin in normal humans results in local and systemic inflammatory responses. Am J Resp Crit Care Med 153:A442, 1995
76. Clapp WD, Becker S, Quay J, et al.: Grain dust-induced airflow obstruction and inflammation of the lower respiratory tract. Am J Respir Crit Care Med 150:611-617, 1994
77. von der Mohlen MA, Kimmings AN, Wedel NI, et al.: Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 172:144-151, 1995
78. Bunnell E, Lynn M, Parrillo JE, Habet K, Friedhoff LT, Rogers SL: Effect of E5531 on systemic responses to endotoxin in healthy volunteers. Crit Care Med 23 (Suppl):A147, 1995
79. Pajkrt D, Doran JE, Koster F, et al.: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184:1601-1608, 1996
80. Barber AE, Coyle SM, Marano MA, et al.: Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150:1999-2006, 1993
81. Van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713-719, 1996
82. Granowitz EV, Porat R, Mier JW, et al.: Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 82:2985-2990, 1993
83. Van der Poll T, Coyle SM, Levi M, et al.: Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 89:3727-3734, 1997
84. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, et al.: Recombinant tumor necrosis factor receptor (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal human subjects. Thromb Haemost 80:114-118, 1997
85. Pajkrt D, Camoglio L, Tiel-van Buul MCM, et al.: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia. J Immunol. 158:3971-3977, 1997
86. Pollmacher T, Korth C, Mullington J, et al.: Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87:900-905, 1996
87. Pajkrt D, Manten A, Van der Poll T, et al.: Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1415-1424, 1997